Given the systemic pathology caused by aberrant GSK3β activity in glucose intolerance and chronic inflammation [71], GSK3β inhibition may decrease the risk of developing pancreatic cancer by improving these conditions. This evidence concerns the gene GSK3B and pancreatic neoplasm.